163 related articles for article (PubMed ID: 12883494)
1. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.
Imazeki F; Yokosuka O; Fukai K; Saisho H
Hepatology; 2003 Aug; 38(2):493-502. PubMed ID: 12883494
[TBL] [Abstract][Full Text] [Related]
2. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response.
Imai Y; Kasahara A; Tanaka H; Okanoue T; Hiramatsu N; Tsubouchi H; Yoshioka K; Kawata S; Tanaka E; Hino K; Hayashi K; Tamura S; Itoh Y; Sasaki Y; Kiyosawa K; Kakumu S; Okita K; Hayashi N
J Gastroenterol; 2004 Nov; 39(11):1069-77. PubMed ID: 15580400
[TBL] [Abstract][Full Text] [Related]
3. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of chronic hepatitis C: results of a large, prospective cohort study.
Niederau C; Lange S; Heintges T; Erhardt A; Buschkamp M; Hürter D; Nawrocki M; Kruska L; Hensel F; Petry W; Häussinger D
Hepatology; 1998 Dec; 28(6):1687-95. PubMed ID: 9828236
[TBL] [Abstract][Full Text] [Related]
5. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
[TBL] [Abstract][Full Text] [Related]
7. Long-term cohort study of chronic hepatitis C according to interferon efficacy.
Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
J Gastroenterol Hepatol; 2012 Feb; 27(2):291-9. PubMed ID: 21793911
[TBL] [Abstract][Full Text] [Related]
8. Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C.
Imazeki F; Yokosuka O; Fukai K; Kawai S; Kanda T; Kojima H; Saisho H
Liver Int; 2005 Aug; 25(4):772-8. PubMed ID: 15998428
[TBL] [Abstract][Full Text] [Related]
9. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
Kobayashi S; Takeda T; Enomoto M; Tamori A; Kawada N; Habu D; Sakaguchi H; Kuroda T; Kioka K; Kim SR; Kanno T; Ueda T; Hirano M; Fujimoto S; Jomura H; Nishiguchi S; Seki S
Liver Int; 2007 Mar; 27(2):186-91. PubMed ID: 17311612
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.
van Zonneveld M; Honkoop P; Hansen BE; Niesters HG; Darwish Murad S; de Man RA; Schalm SW; Janssen HL
Hepatology; 2004 Mar; 39(3):804-10. PubMed ID: 14999700
[TBL] [Abstract][Full Text] [Related]
11. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
[TBL] [Abstract][Full Text] [Related]
12. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.
Di Martino V; Thevenot T; Colin JF; Boyer N; Martinot M; Degos F; Coulaud JP; Vilde JL; Vachon F; Degott C; Valla D; Marcellin P
Gastroenterology; 2002 Dec; 123(6):1812-22. PubMed ID: 12454838
[TBL] [Abstract][Full Text] [Related]
13. Necessities of interferon therapy in elderly patients with chronic hepatitis C.
Ikeda K; Arase Y; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
Am J Med; 2009 May; 122(5):479-86. PubMed ID: 19375558
[TBL] [Abstract][Full Text] [Related]
14. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.
Huang JF; Yu ML; Lee CM; Dai CY; Hou NJ; Hsieh MY; Wang JH; Lu SN; Sheen IS; Lin SM; Chuang WL; Liaw YF
Aliment Pharmacol Ther; 2007 May; 25(9):1029-37. PubMed ID: 17439503
[TBL] [Abstract][Full Text] [Related]
15. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy.
Yu ML; Lin SM; Lee CM; Dai CY; Chang WY; Chen SC; Lee LP; Lin ZY; Hsieh MY; Wang LY; Chuang WL; Liaw YF
Hepatology; 2006 Nov; 44(5):1086-97. PubMed ID: 17058238
[TBL] [Abstract][Full Text] [Related]
16. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
Bressler BL; Guindi M; Tomlinson G; Heathcote J
Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
[TBL] [Abstract][Full Text] [Related]
17. Determinants of outcome of compensated hepatitis C virus-related cirrhosis.
Serfaty L; Aumaître H; Chazouillères O; Bonnand AM; Rosmorduc O; Poupon RE; Poupon R
Hepatology; 1998 May; 27(5):1435-40. PubMed ID: 9581703
[TBL] [Abstract][Full Text] [Related]
18. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Aug; 79(8):1095-102. PubMed ID: 17597485
[TBL] [Abstract][Full Text] [Related]
19. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
[TBL] [Abstract][Full Text] [Related]
20. [Hepatitis C: epidemiology and therapy--with special reference to long-term prognosis after IFN therapy].
Fujiyama S; Tanaka M
Rinsho Byori; 2000 Jan; 48(1):5-13. PubMed ID: 10756668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
